UroGen Pharma Ltd. (URGN)
After hours:
| Previous Close | 14.26 |
| Open | 14.50 |
| Bid | 14.24 x 200 |
| Ask | 14.29 x 200 |
| Day's Range | 14.14 - 14.70 |
| 52 Week Range | 8.69 - 24.13 |
| Volume | |
| Avg. Volume | 352,398 |
| Market Cap | 516.66M |
| Beta (5Y Monthly) | 1.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.55 |
| Earnings Date | May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 38.50 |
Business WireUroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
PRINCETON, N.J, May 04, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier methods the probabilities of remaining in complete response for both new and recurrent low-grade intermediate-risk non- muscle invasive bladder cancer (LG-IR-NMIBC) patients following treatment with investiga
Business WireNew Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
PRINCETON, N.J., May 04, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO (mitomycin) for pyelocalyceal solution presented at the American Urological Association Meeting 2024 in San Antonio, TX. The study includes a stepwise approach to retrograde administration of JELMYTO and reports t
Business WireUroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
PRINCETON, N.J., May 03, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2024 first quarter financial results on Monday, May 13, 2024, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
